Dr. Hesketh is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
Mall Rd
# 41
Burlington, MA 01805Phone+1 781-744-8400Fax+1 781-744-5245
Summary
- I am a board certified oncologist and Chair of Lahey Health Cancer Institute in Burlington, Massachusetts.
Education & Training
- Boston University Medical CenterFellowship, Hematology and Medical Oncology, 1983 - 1984
- Boston University Medical CenterFellowship, Hematology and Medical Oncology, 1981 - 1983
- St Elizabeth's Medical CenterResidency, Internal Medicine, 1978 - 1981
- Uconn School Of MedicineClass of 1978
Certifications & Licensure
- NH State Medical License 2024 - 2026
- MA State Medical License 1980 - 2025
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Boston Magazine Castle Connolly, 2010-2013
- Super Doctor SuperDoctors.com
- Top MD Consumers Checkbook
Clinical Trials
- S0027: Vinorelbine Followed by Docetaxel in Treating Patients With Advanced Non-Small Cell Lung Cancer Start of enrollment: 2001 Nov 01
- S0341: Erlotinib in Treating Patients With Advanced Primary Non-Small Cell Lung Cancer Start of enrollment: 2004 Sep 01
- S0709: Erlotinib With or Without Carboplatin and Paclitaxel in Stage IIIB or Stage IV Non-Small Cell Lung Cancer Start of enrollment: 2008 Dec 01
- Join now to see all
Publications & Presentations
PubMed
- 95 citations2016 Updated MASCC/ESMO Consensus Recommendations: Prevention of Nausea and Vomiting Following High Emetic Risk ChemotherapyJørn Herrstedt, Fausto Roila, David Warr, Luigi Celio, Rudolph M. Navari
Supportive Care in Cancer. 2017-01-01 - 159 citationsEfficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic...Paul J. Hesketh, G. Rossi, Giada Rizzi, Marco Palmas, Anna Alyasova
Annals of Oncology. 2014-07-01 - 21 citationsTreatment of Oligometastatic Non-Small Cell Lung Cancer: An ASTRO/ESTRO Clinical Practice Guideline.Puneeth Iyengar, Sean All, Mark F Berry, Thomas P Boike, Lisa Bradfield
Practical Radiation Oncology. 2023-04-25
Other
- Characteristics of antiemetic drugsHesketh PJ, Longstreth GF
http://www.uptodate.com/contents/characteristics-of-antiemetic-drugs
UpToDate, Wolters Kluwer Health - 2013-02-18 - Pathophysiology and prediction of chemotherapy-induced nausea and vomitingHesketh PJ
http://www.uptodate.com/contents/pathophysiology-and-prediction-of-chemotherapy-induced-nausea-and-v
UpToDate, Wolters Kluwer Health - 2012-10-01 - Prevention and treatment of chemotherapy-induced nausea and vomitingHesketh PJ
http://www.uptodate.com/contents/prevention-and-treatment-of-chemotherapy-induced-nausea-and-vomitin
UpToDate, Wolters Kluwer Health - 2013-03-08
Press Mentions
- Cancer Survivorship Program Goes the Extra MileJuly 18th, 2019
- Management of Chemotherapy-Induced Nausea & VomitingDecember 10th, 2017
- How to Succeed in Modernizing Clinical TrialsJanuary 10th, 2017
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: